Table 1

Epithelial to mesenchymal transition (EMT) related genes modified in a clone expressing a dominant-negative form of SNAI1 (SNAI1-DN) in comparison with MDA-mock control cells

GenBank number

SNAI1-DN

Description

EMT related (n = 9)

[Genbank:AA447737]

-2.12

CALD1, caldesmon 1

[Genbank:AA284668]

-2.45

PLAU, plasminogen activator, urokinase

[Genbank:AA136707]

-2.12

PLOD2, procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase) 2

[Genbank:N75719]

-7.22

SERPINE1, serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1

[Genbank:H96738]

2.29

CDH11, cadherin 11, type 2, OB-cadherin (osteoblast)

[Genbank:H15267]

2.48

CHL1, cell adhesion molecule with homology to L1CAM (close homologue of L1)

[Genbank:AA598794]

3.87

CTGF, connective tissue growth factor

[Genbank:W51794]

3.49

MMP3, matrix metalloproteinase 3 (stromelysin 1, progelatinase)

[Genbank:AA479202]

2.58

TIMP3, tissue inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy, pseudo-inflammatory)

Nine of the 99 target genes differentially expressed in SNAI1-DN clone are implicated in the EMT process and matrix remodelling, including some members of the plasminogen activation system. Particularly, the expression of PAI-1 is decreased by 7.2-fold in SNAI1-DN clones. - = down-regulation; + = up-regulation.

Fabre-Guillevin et al. Breast Cancer Research 2008 10:R100   doi:10.1186/bcr2203